Although EGFR-TKI have become a first-line inhibitor of EGFR mutation-positive NSCLC, nearly half of NSCLC patients are resistant to EGFR-TKI-based chemotherapies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.